Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson speaks with Proactive soon after announcing the company has formed a partnership with v2vmedtech, Inc. to create a novel heart valve repair device for minimally invasive treatment of mitral and tricuspid valve regurgitation, also known as a leaky valve. This cutting-edge technology is a valuable addition to Anteris' portfolio, allowing the company to expand into a market adjacent to transcatheter aortic valve replacement (TAVR) - a market expected to reach A$4.1 billion by 2028.
Anteris says new repair device provides another shot on goal for multi-billion dollar product
